BCL-2是细胞凋亡信号途径中的重要靶分子,发挥抑制细胞凋亡的作用。venetoclax为一种口服选择性BCL-2抑制剂,通过与BCL-2结合,恢复肿瘤细胞的正常凋亡途径,从而发挥抗肿瘤的作用。venetoclax已获美国FDA批准用于单独治疗曾接受过至少一种治疗方案的染色体17p缺失的慢性淋巴细胞白血病患者。其常见的不良反应包括中性粒细胞减少、腹泻、恶心、贫血、血小板减少、上呼吸道感染及疲劳等。 BCL-2 is an important target in the apoptotic signaling pathway and plays a role in inhibiting apoptosis. Venetoclax, an orally administered BCL-2 inhibitor, regulates the normal apoptotic pathways of tumor cells by binding to BCL-2, thereby exerting antitumor effects. venetoclax has been approved by the U.S. FDA for the treatment of Chronic Lymphocytic Leukemia patients with chromosome 17p deletion who have previously received at least one regimen of treatment. Common adverse reactions include neutropenia, diarrhea, nausea, anemia, thrombocytopenia, upper respiratory tract infections and fatigue.